Theragen Bio is conducting new drug development research with the goal of contributing to
the improvement of the survival rate of cancer patients by developing treatments for darkmatter cancer,
which currently has no treatment and a poor prognosis.

Theragen Bio is developing a truly personalized cancer treatment based on therapeutic neoepitope vaccine. We developed and patented DeepOmicsNeo™, a deep learning based neoepitope prediction algorithm, with a superior positive predictive value compared to competing algorithms, for this purpose.
Theragen Bio vaccine design proved to have a superior efficacy over conventional neoepitope vaccine design in a preclinical study.
We aim to launch phase 1 clinical trial by the end of 2023.

EMT molecular subtype rectal cancer and CMS4 molecular subtype colorectal cancer are typical darkmatter cancers with poor prognosis even after chemotherapy, therefore, Theragen Bio discovered a number of new targets in those cancers through DeepOmics™ analysis,
a deep learning-based genome analysis platform, and is developing targeted therapies for them.